ACP-103 + haloperidol

**ACP-103 + haloperidol** is a combination therapy of two drugs: ACP-103 (also known as pimavanserin), a selective serotonin 5-HT2A receptor inverse agonist, and haloperidol, a typical antipsychotic that primarily acts as a dopamine D2 receptor antagonist. This combination has been studied for the treatment of schizophrenia, with the goal of improving antipsychotic efficacy, accelerating onset of therapeutic action, and reducing unwanted side effects like weight gain and motor disturbances associated with haloperidol monotherapy. ACP-103, developed by Acadia Pharmaceuticals, is designed to modulate serotonergic activity, potentially enhancing the efficacy of antipsychotic treatments by targeting the serotonin system alongside dopamine blockade. The combination aims to provide improved symptom control, more rapid therapeutic effects, and a more favorable side effect profile compared to haloperidol alone[1][3][5].

Other names

ACP-103 and haloperidolACP103 and haloperidolACP 103 and haloperidolpimavanserin and haloperidol